A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients
Status:
Completed
Trial end date:
2002-01-01
Target enrollment:
Participant gender:
Summary
This is a dosage escalation study to estimate the maximum tolerated dose of 9-cis-retinoic
acid given in combination with tamoxifen. Groups of 3 to 6 patients receive oral
9-cis-retinoic acid daily for 4 weeks, after which daily oral tamoxifen is added to the
regimen. Patients continue treatment for up to 28 weeks, with tamoxifen continued after the
study if medically appropriate.